Canadian Society of Hematology   Report issue

Foundation Phase 2
Founded: Ottawa Canada (1971)

Organization Overview

First Clinical Trial
2020
NCT04243122
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Canadian Society of Hematology

Active Ingredients

Drugs in Phase 2 Trials (2)

acetylsalicylic acid (aspirin) (1 trial)

apixaban (eliquis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myeloproliferative Disorders (Phase 2)

Neoplasms (Phase 2)

Polycythemia (Phase 2)

Polycythemia Vera (Phase 2)

Primary Myelofibrosis (Phase 2)

Thrombocythemia, Essential (Phase 2)

Thrombocytosis (Phase 2)

Thromboembolism (Phase 2)

Venous Thromboembolism (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2